Cantor Fitzgerald’s Immunome IMNM Stock Holding History

Cantor Fitzgerald’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-21,000	Closed	-$195K	–	457
2025 Q2	$195K	Buy	+21,000	New	+$172K	﹤0.01%	308

Other funds holding IMNM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Cantor Fitzgerald's IMNM Position: Q3 2025 in Review

Cantor Fitzgerald sold out of Immunome (IMNM) in Q3 2025, closing a stake of 21,000 shares — an estimated $195K sold.

Cantor Fitzgerald first reported a position in IMNM in Q2 2025 and held it in 1 quarter. The position peaked at $195K in Q2 2025. 153 funds tracked by Wall St. Rank hold IMNM as of Q3 2025.

Cantor Fitzgerald reported no remaining Immunome position as of Q3 2025 after selling out during the quarter.
Cantor Fitzgerald sold 21,000 Immunome shares in Q3 2025, an estimated $195K.
Cantor Fitzgerald first reported a position in Immunome in Q2 2025 and held it in 1 quarter.
Cantor Fitzgerald's Immunome position peaked at $195K in Q2 2025.
153 funds tracked by Wall St. Rank held Immunome as of Q3 2025.

Based on Cantor Fitzgerald's 13F filing for Q3 2025, filed 14 Nov 2025.